ADIMAB
Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.
ADIMAB
Industry:
Biotechnology Collaboration Health Care Therapeutics
Founded:
2007-05-01
Address:
Lebanon, New Hampshire, United States
Country:
United States
Website Url:
http://www.adimab.com
Total Employee:
101+
Status:
Active
Contact:
(603) 643-7110
Email Addresses:
[email protected]
Total Funding:
45.48 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress Google Analytics Global Site Tag IPv6
Similar Organizations
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
XOMA
XOMA is at the forefront of antibody discovery and development, one of the most powerful and transformative fields of drug innovation
Current Advisors List
Current Employees Featured
Founder
Investors List
Lux Capital
Lux Capital investment in Venture Round - Adimab
SV Health Investors
SV Health Investors investment in Series F - Adimab
Polaris Partners
Polaris Partners investment in Series F - Adimab
Google Ventures
Google Ventures investment in Series F - Adimab
Google Ventures
Google Ventures investment in Series D - Adimab
Polaris Partners
Polaris Partners investment in Series D - Adimab
Borealis Ventures
Borealis Ventures investment in Series D - Adimab
OrbiMed
OrbiMed investment in Series D - Adimab
SV Health Investors
SV Health Investors investment in Series D - Adimab
SV Health Investors
SV Health Investors investment in Series C - Adimab
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-04-19 | Invivyd | Adimab investment in Series C - Invivyd | 336 M USD |
| 2020-07-16 | Invivyd | Adimab investment in Series A - Invivyd | 50 M USD |
Key Employee Changes
| Date | New article |
|---|---|
| 2022-05-09 | Adimab Announces Promotions of New Chief Executive Officer and President |
Official Site Inspections
http://www.adimab.com Semrush global rank: 4.7 M Semrush visits lastest month: 1.97 K
- Host name: 19.98.212.35.bc.googleusercontent.com
- IP address: 35.212.98.19
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Adimab"
Who We Are - Adimab
Ryan McGovern is the Chief Financial Officer of Adimab and has been with the company since 2010. Before joining Adimab, Mr. McGovern served as Advisory Council for Live Free and …See details»
Adimab - Crunchbase Company Profile & Funding
Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of …See details»
Adimab Company Profile | Management and Employees List
Adimab Profile and History. Adimab is the leading provider of therapeutic antibody discovery and engineering technologies. This includes nave discovery from synthetic libraries in yeast or B …See details»
Adimab Company Profile 2024: Valuation, Funding
Adimab General Information Description. Developer of yeast-based therapeutic human antibodies designed to improve the quality of the therapeutic lead. The company's therapeutic human antibodies involve the discovery, maturation, …See details»
Adimab - Org Chart, Teams, Culture & Jobs - The Org
View Adimab's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Adimab Company Profile: Overview and Full News Analysis
Adimab is a leading provider of biologics discovery and engineering. They have generated over 500 therapeutic programs through industry partnerships. Adimab's proprietary yeast-based …See details»
Adimab - Company Profile - Tracxn
Dec 13, 2024 Adimab - Antibody discovery and optimization platform for autoimmune and infectious diseases. Raised a total funding of $35.4M over 6 rounds from 11 investors. …See details»
Adimab - Funding, Financials, Valuation & Investors - Crunchbase
Adimab is funded by 6 investors. Lux Capital and SV Health Investors are the most recent investors. Adimab has a post-money valuation in the range of $100M to $500M as of Apr 1, …See details»
Adimab Company Profile - Office Locations, Competitors, Revenue …
Adimab is a biotechnology company that provides a discovery platform functioning as a synthetic human immune system. It helps to develop antibody therapeutics across a range of medical …See details»
Adimab - VentureRadar
Adimab’s integrated antibody discovery and engineering platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by …See details»
Adimab Company Overview, Contact Details & Competitors | LeadIQ
Adimab is the most successful antibody discovery company in the industry, with 450+ discovery campaigns and 55+ clinical programs created with more than 100 partners. Our unique, yeast …See details»
Adimab - Contacts, Employees, Board Members, Advisors
Organization. Adimab . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... Adimab has 8 current employee profiles, including Co …See details»
Platform - Adimab
Adimab’s best-in-class capabilities are made possible by combining our proprietary technology with our vast operational experience. De novo antibody discovery and optimization Adimab …See details»
Adimab, the secret weapon of the Big Pharma companies
Feb 23, 2015 After establishing discovery collaborations with over 30 companies during the past five years (Roche, Pfizer, Genentech, Novartis, Merck, Lilly, Celgene, Novo Nordisk and …See details»
Ono Enters into a Drug Discovery Collaboration Agreement with …
Sep 27, 2023 About Adimab, LLC Adimab is the leading provider of therapeutic antibody discovery and engineering technologies. This includes naïve discovery from synthetic libraries …See details»
Technology - Adimab
Adimab has optimized over a thousand individual antibodies on the basis of specificity, potency, and/or developability. This robust process relies on AI and ML-guided library diversities, facile …See details»
Working At Adimab: Company Overview and Culture - Zippia
Mar 14, 2024 Adimab is a small health care company based in Lebanon, NH with only 128 employees and an annual revenue of $15.0M. Adimab's Mission Statement To focus on …See details»
News - Adimab
Adimab Announces Hire of Aaron Sato as Chief Strategy Officer. January 10, 2024. Adimab Announces Substantial Expansion of Research Campus. January 9, 2024. Adimab Provides …See details»
Adimab Provides 2021 Update on Clinical Pipeline
Jan 19, 2022 Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that 12 new partner programs entered …See details»